Vimarsana
Biggest News Aggregation in the World

Page 25 - Cath Lab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cath Lab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cath Lab Today - Breaking & Trending Today

PLI Schemes witness over Rs 1.03 lakh crore of investment till Nov 2023 | Indiablooms - First Portal on Digital News Management - Vimarsana News

PLI Schemes witness over Rs 1.03 lakh crore of investment till Nov 2023 | Indiablooms - First Portal on Digital News Management

New Delhi: Production Linked Incentive (PLI) Schemes witnessed over Rs. 1.03 lakh crore of investment till November 2023, leading to production/ sales of Rs. 8.61 lakh crore and direct and indirect employment generation of over 6.78 lakhs, according to the Commerce and Industry ministry. 

Inclisiran for cholesterol: Docs call it expensive, bat for cheaper options - Vimarsana News

Inclisiran for cholesterol: Docs call it expensive, bat for cheaper options

Even as India is set to soon launch promising new DCGI and US FDA-approved medicine Inclisiran to lower cholesterol and keep it low with just two doses a year, doctors, while hailing the advance, contend that the drug is expensive and stressed ...

Inclisiran For Cholesterol: Docs Call It Expensive, Bat For Cheaper Options (Lead) - Vimarsana News

Inclisiran For Cholesterol: Docs Call It Expensive, Bat For Cheaper Options (Lead)

New Delhi, Jan 14 (IANS) Even as India is set to soon launch promising new DCGI and US FDA-approved medicine Inclisiran to lower cholesterol and keep it low

Inclisiran for cholesterol: Docs call it expensive, stress for cheaper options - Vimarsana News

Inclisiran for cholesterol: Docs call it expensive, stress for cheaper options

Even as India is set to soon launch promising new medicine called the DCGI and US FDA-approved Inclisiran to lower cholesterol and keep it low with just two doses a year, doctors while hailing the advance contend that the drug is expensive and ...

Inclisiran for cholesterol: Docs call it expensive, bat for cheaper options - Vimarsana News

Inclisiran for cholesterol: Docs call it expensive, bat for cheaper options

Even as India is set to soon launch promising new DCGI and US FDA-approved medicine Inclisiran to lower cholesterol and keep it low with just two doses a year, doctors, while hailing the advance, contend that the drug is expensive and stressed on better use of the much cheaper versions available.